ABSTRACT
Sixty-five adult patients who had acute peripheral vestibulopathy (APV) were followed-up to determine their functional outcome. During the acute phase, they were treated with betahistine and mobilization. In the entire study population, APV was not significantly associated with a change in occupational activities, physical work or driving ability. Older individuals had significantly attributed a change in work to disease other than APV. Change attributed to APV occurred significantly more frequently in women than in men. The therapeutic approach seems beneficial.
Subject(s)
Betahistine/administration & dosage , Vasodilator Agents/administration & dosage , Vestibular Neuronitis/drug therapy , Vestibular Neuronitis/physiopathology , Adult , Age Factors , Aged , Aged, 80 and over , Automobile Driving , Female , Humans , Male , Middle Aged , Motion , Retrospective Studies , Sex Factors , Time Factors , Treatment Outcome , WorkABSTRACT
We reviewed 36 reported psychiatric patients who were treated with a combination of electroconvulsive therapy (ECT) and clozapine. The indication of the ECT-clozapine treatment was resistance to classical antipsychotic agents, clozapine, or ECT alone. Sixty-seven percent of the patients benefited from the combined treatment. In most of the patients, the combined treatment was safe and well tolerated. Adverse reactions occurred in 16.6% of the patients and included prolonged ECT-induced seizures (one case), supraventricular (one case) and sinus tachycardia, and blood pressure elevation. It seems that combined ECT-clozapine treatment is effective and safe. This strategy may be a therapeutic option in treatment-resistant patients.
Subject(s)
Antipsychotic Agents/therapeutic use , Clozapine/therapeutic use , Electroconvulsive Therapy , Psychotic Disorders/therapy , Adult , Bipolar Disorder/drug therapy , Bipolar Disorder/therapy , Combined Modality Therapy , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/therapy , Female , Humans , Male , Psychotic Disorders/drug therapy , Schizophrenia/drug therapy , Schizophrenia/therapyABSTRACT
The aim of this study was to evaluate the effect of long-term clozapine treatment on body weight changes in neuroleptic-resistant chronic schizophrenic patients and to compare it with that of classical antipsychotic agents. The body mass index (BMI) of 96 neuroleptic-resistant chronic schizophrenic patients was calculated before the beginning and after long-term (mean +/- SD 1.7 +/- 1.3 years) clozapine treatment. These data were compared to the BMI of 98 chronic schizophrenic patients maintained on classical antipsychotic agents for a similar duration (mean +/- SD 1.9 +/- 1.6 years). A significant elevation in BMI was detected in both groups during these periods (P < 0.0001 versus baseline, for both groups). The change in BMI (delta BMI) was similar in both groups (P < 0.9). We conclude that the increase in body weight caused by long-term (> 6 months) clozapine treatment is comparable to that obtained following long-term classical antipsychotic agents treatment.
